TY - JOUR
T1 - Factors associated with the successful modification of antiretroviral therapy
AU - Weidle, Paul J.
AU - Lichtenstein, Kenneth A.
AU - Moorman, Anne C.
AU - Von Bargen, Jennifer C.
AU - Greenberg, Kenneth S.
AU - Palella, Frank J.
AU - Holmberg, Scott D.
PY - 2000
Y1 - 2000
N2 - Objectives: To assess the characteristics of medication regimen modification and the influence of a commercial genotypic resistance assay on the short-term (3-12 weeks) viral load response (≥ 0.5 log reduction) in HIV-1-infected patients extensively treated with antiretroviral therapy (ART). Methods: A nested cohort study was performed in two clinics from the HIV Outpatient Study of 96 persons with a HIV-1 viral load of 104 log copies/ml or greater taking at least two antiretroviral medications. Results: Successful modification was associated with adding at least two new medications [relative risk (RR), 1.5; 95% confidence interval (CI), 1.1-2.2], adding a drug from a previously unused class of agents (RR 2.0; CI, 1.4-2.9), the initiation of a non nucleoside reverse transcriptase inhibitor (NNRTI) (RR, 1.7; CI, 1.2-2.4), but not substituting a protease inhibitor or the use of a commercial genotypic resistance assay. Conclusion: Incorporating a drug from a previously unused class or changing at least two new medications, but, within the confines of this study, not using a commercial genotypic resistance assay, was associated with the successful modification of ART as measured by a reduction in viral load. (C) 2000 Lippincott Williams and Wilkins.
AB - Objectives: To assess the characteristics of medication regimen modification and the influence of a commercial genotypic resistance assay on the short-term (3-12 weeks) viral load response (≥ 0.5 log reduction) in HIV-1-infected patients extensively treated with antiretroviral therapy (ART). Methods: A nested cohort study was performed in two clinics from the HIV Outpatient Study of 96 persons with a HIV-1 viral load of 104 log copies/ml or greater taking at least two antiretroviral medications. Results: Successful modification was associated with adding at least two new medications [relative risk (RR), 1.5; 95% confidence interval (CI), 1.1-2.2], adding a drug from a previously unused class of agents (RR 2.0; CI, 1.4-2.9), the initiation of a non nucleoside reverse transcriptase inhibitor (NNRTI) (RR, 1.7; CI, 1.2-2.4), but not substituting a protease inhibitor or the use of a commercial genotypic resistance assay. Conclusion: Incorporating a drug from a previously unused class or changing at least two new medications, but, within the confines of this study, not using a commercial genotypic resistance assay, was associated with the successful modification of ART as measured by a reduction in viral load. (C) 2000 Lippincott Williams and Wilkins.
KW - Antiretroviral therapy
KW - Genotypic
KW - Modification
KW - Resistance
UR - http://www.scopus.com/inward/record.url?scp=0034073039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034073039&partnerID=8YFLogxK
U2 - 10.1097/00002030-200003310-00004
DO - 10.1097/00002030-200003310-00004
M3 - Article
C2 - 10780711
AN - SCOPUS:0034073039
SN - 0269-9370
VL - 14
SP - 491
EP - 497
JO - AIDS
JF - AIDS
IS - 5
ER -